

References

1. Babii LM. Osoblyvosti perebihu, predyctory i prognozuvannia naslidkiv ishemichnoi khvoroby sercia u chvorych, yaki perenesly infarkt miokarda, za danymy dvorichnoho sposterezhennia. Autoreferat doktorskoi dysertacii. TOV «Firma IMIDZH», Kyiv, 2000.36p (in Ukr).
2. Gorbas IM. Kontrol arterialnoi hipertenzii sered naseleattia: stan problemy za danymy epidemiolohichnykh doslidzhen. *Ukrainskyi kardiolohichnyi zhurnal – Ukr J Cardiol* 2007;2:21–26 (in Ukr).
3. Kovalenko VM, Lutai MI, Svishchenko YeP, Sirenko YuM, Smirnova IP. Rekomendacii Ukrainskoho tovarystva kardiolohiv z profilaktyky ta likuvannia arterialnoi hipertenzii. Kyiv, VIPOL, 2004.84p (in Ukr).
4. Nastanova ta klinichnyi protokol nadannia medychnoi dopomogy «Arterialna hipertensiiia». Nakaz MOZ Ukrainy vid 24.05.2012. Kyiv,2012.107p (in Ukr).
5. Chendei TV. Osoblyvosti perebihu ta likuvannia ishemichnoi khvoroby sercia, poiednanoi z arterialnoiu hipertenziieiu u meshkantsiv hirsanoi zony Zakarpattia. Autoreferat kandydatskoi dysertatsii – UZHHOROD,2008.12p (in Ukr).
6. 2013 ESH/ESC Guidelines for the management of arterial hypertension TheTask Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertension* 2013;31:1281–357.
7. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium channel blocker or diuretic in the International Nifedipine GITIS study: Intervention as a GOAL in Hypertension Treatment (INSIGHT). *Lancet* 2000;356:366–72.
8. Chemla D, Hébert JL, Coirault C, Zamani K, Suard I, Colin P, Lecarpentier Y. Total arterial compliance estimated by stroke volume-to-aortic pulse pressure ratio in humans. *Am J Physiol* 1998;274:500–5.
9. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, Lanke J, de Faire U, Dahlöf B, Karlberg BE for NORDIL Study group. Randomised trial of effects of calcium antagonists compared with diuretics and b-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. *Lancet* 2000;356:339–65.
10. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmäki K, Dahlöf B, de Faire U, Mörlin C, Karlberg BE, Wester PO, Björck JE. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity in hypertension: the Captopril Preventional Project (CAPP) randomised trial. *Lancet* 1999;353:611–6.
11. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling S. for the HOT Study Group. Effects of intense blood pressure lowering and low-dose aspirin in patients with hypertension. Principal results of the Hypertension Optimal Treatment (HOT) randomized trial. *Lancet* 1998;351:1755–62.
12. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. *JAMA* 1996;275:1572–6.

13. Lenter C. Geigy Scientific Tables. CIBA-GEIGY Corporation: Basel,1990.278 p.
14. Mancia G, Messerli F, Bakris G, Zhou Q, Champion A, Pepine CJ. Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. *Hypertension* 2007;50:299–305.
15. Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, Champion A, Kolloch R, Benetos A, Pepine CJ. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? *Ann Intern Med* 2006;144:884–93.
16. Okin PM, Devereux RB, Liu JE, Oikarinen L, Jern S, Kjeldsen SE, Julius S, Wachtell K, Nieminen MS, Dahlöf B. Regression of electrocardiographic left ventricular hypertrophy predicts regression of echocardiographic left ventricular mass: the LIFE study. *J Human Hypertens* 2004;18:403–9.
17. Pastor-Barriuso R, Banegas JR, Damián J, Appel LJ, Guallar E. Systolic blood pressure, diastolic blood pressure and pulse pressure: an evaluation of their joint effect on mortality. *Ann Intern Med* 2003;139:731–9.
18. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, Mancia G, Cangiano JL, Garcia-Barreto D, Keltai M, Erdine S, Bristol HA, Kolb HR, Bakris GL, Cohen JD, Parmley WW. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomised controlled trial. *JAMA* 2003;290:2805–16.
19. Persson M, Carlberg B, Tavelin B, Lindholm L. Doctor's estimation of cardiovascular risk and willingness to give drug treatment in hypertension: fair risk assessment but defensive treatment policy. *J Hypertens* 2004;22:65–71.
20. Prospective Study Collaboration. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. *Lancet* 2009;373:1083–96.
21. Schillaci G, Parati G. Ambulatory artery stiffness index: merits and limitations of a simple surrogate measure of arterial compliance. *J Hypertens* 2008;26:182–5.
22. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). *JAMA* 1991;265:3255–64.
23. Sierra C, Coca A. The ACTION Study: Nifedipine in Patients With Symptomatic Stable Angina and Hypertension. *Expert Rev Cardiovasc Ther* 2008;6(8):1055–62.
24. Sleight P, Redon J, Verdecchia P, Mancia G, Gao P, Fagard R, Schumacher H, Weber M, Böhm M, Williams B, Pogue J, Koon T, Yusuf S. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. *J Hypertens* 2009;27:1360–9.
25. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to Doxazosin vs chlorthalidone. The Antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). *JAMA* 2000;283:1967–75.

26. The ALLHAT Officers and Coordinators. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA* 2002;288:2981–97.
27. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. *N Engl J Med* 2000;342:145–53.
28. The ONTARGET Investigators. Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. *N Engl J Med* 2008;358:1547–59.
29. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. US Department of Health and Human Service. NIH Publication No. 03-5233, 2003.34p.
30. Trivadi H, Pang M. Discrepancy in epidemiology of nondiabetic chronic renal insufficiency and end-stage renal disease in black and white Americans: the third National Health and Nutrition Examination Survey and United States Renal data System. *Am J Nephrol* 2003;23:448–57.
31. White W. Blood pressure monitoring in cardiovascular medicine and therapeutics. *New Jersey*: HUMANA PRESS, 2001.308p.
32. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. *Lancet* 2004;364:937–52.